孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘疗效分析.doc

孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘疗效分析 　　[摘要] 目的 探讨孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘的临床疗效。 方法 将2012年5月～2014年11月间我院小儿内科收治的140例小儿咳嗽变异性哮喘患者分为观察组及对照组，两组均实施常规治疗，同时对照组予布地奈德吸入剂治疗，观察组在对照组的基础上联合孟鲁司特实施治疗，且在出院后实施随访观察，8周后比较两组患儿的临床疗效及肺功能改善情况。 结果 治疗结束后，观察组的临床有效率为98.6%，明显优于对照组（87.1%），且具有统计学意义（P0.05）；肺功能方面，两组患儿的FEV1、FVC、FEV1/FVC较前均有不同程度的改善，但观察组改善更为明显，且其改善程度与对照组比较存在差异性（P0.05）。 结论 孟鲁司特联合布地奈德可有效改善患儿的临床症状及肺功能情况，有利于尽快控制病情，改善患儿预后。 　　[关键词] 孟鲁司特；布地奈德；咳嗽变异性哮喘 　　[中图分类号] R725.6 [文献标识码] B [文章编号] 1673-9701（2015）09-0073-03 　　Curative effect analysis of montelukast combined budesonide in the treatment of infantile cough variant asthma 　　YIN Xiuqin 　　Department of Pharmacy， Shandong Zibo Central Hospital， Zibo 255036， China 　　[Abstract] Objective To explore the efficacy of montelukast and budesonide in treatment of children with cough variant asthma. Methods A total of 140 children with cough variant asthma were randomly divided into the observation group and control group in our hospital from May 2012 to November 2014. All children were given conventional treatment. At the same time， the control group was given budesonide， while the observation group was given montelukast on basis of the control group， and the clinical curative effect and lung function of the two groups were compared between two groups. Results After the treatment， the clinical effective rate of observation group （98.6%） was better than control group （87.1%）， the FEV1， FVC and FEV1/ FVC of two groups were better than the before， but the observation group was more obvious than the control group （P0.05）. Conclusion Montelukast and budesonide in treatment of children with cough variant asthma can effectively improve clinical symptoms and lung function of children with CVA， and it is helpful to control the condition and improve the prognosis as soon as possible. 　　[Key words] Montelukast；Budesonide；Cough variant asthma 　　咳嗽变异性哮喘（CVA）是一种特殊类型的哮喘，咳嗽是其唯一或主要临床表现，无明显喘息、气促等症状或体征，但有气道高反应性，其临床表现为刺激性干咳，通常咳嗽比较剧烈，夜间咳嗽为其重要特征[1]。CVA临床发病往往存在诱因，如感冒、粉尘、冷空气及油烟等，临床治疗